Disease · HP_0430034
Hypertension resistant to conventional therapy
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Hypertension resistant to conventional therapy. Diseases, record HP_0430034. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0430034
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Hypertension resistant to conventional therapy
- Open Targets ID
- HP_0430034
- Other names
- Resistant hypertension
- Highest stage of its drugs
- Phase 3, for 6 of its 10 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SPIRONOLACTONE | CHEMBL1393 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BAXDROSTAT | CHEMBL4113975 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DARUSENTAN | CHEMBL23261 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HYDROCHLOROTHIAZIDE | CHEMBL435 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LOSARTAN POTASSIUM | CHEMBL995 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ABATACEPT | CHEMBL1201823 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OSILODROSTAT | CHEMBL3099695 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALCOHOL | CHEMBL545 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TILARGININE | CHEMBL256147 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets15
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 3 | https://conductscience.org/library/genes/779 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 2 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 2 | https://conductscience.org/library/genes/942 | Drugs and targets |
| CYP11B1 | Cytochrome P450 11B1, mitochondrial | 1 | Cytochrome P450 11B1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1584 | Drugs and targets |
| EDNRA | Endothelin-1 receptor | 1 | Endothelin receptor ET-A antagonist | Phase 3 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| EDNRB | Endothelin receptor type B | 1 | Endothelin receptor ET-B antagonist | Phase 3 | https://conductscience.org/library/genes/1910 | Drugs and targets |
1 to 10 of 15
See all 15 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00817635 | A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension | Phase 2 | 155 | 2021-06-02 | Hypertension | OSILODROSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01062763 | The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension | Phase 3 | 119 | 2014-05-08 | Arterial Hypertension, Hypertension, Resistant to Conventional Therapy, Diabetes Mellitus | SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov |
| NCT01897727 | Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment | Not applicable | 41 | 2014-01-15 | Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism | SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov |
| NCT02232880 | Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation | Phase 2 | 1 | 2016-08-29 | Hypertension | ABATACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT00389675 | DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension | Phase 3 | 661 | Hypertension | DARUSENTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT02900729 | Randomized Controlled Trial of Renal Denervation for Resistant Hypertension | Phase 3 | 254 | Hypertension | AMLODIPINE, HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT06168409 | A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension | Phase 3 | 218 | Resistant Hypertension | BAXDROSTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT05552300 | Superselective Adrenal Arterial Embolization for Resistant Hypertension | Not applicable | 144 | Resistant Hypertension | ALCOHOL | Its record names the disease | ClinicalTrials.gov | |
| NCT00430794 | The Efficacy of Spironolactone in Patients With Resistant Hypertension | Phase 2 | 40 | Hypertension | SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02039492 | Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension. | Not applicable | 38 | Resistant Arterial Hypertension | SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Addition of Spironolactone vs Placebo: Adverse Effects | 4 of 61 | 0 of 58 | 119 | NCT01062763 | Trial comparisons |
| Addition of Spironolactone vs Placebo: serious adverse events | 1 of 61 | 0 of 58 | 119 | NCT01062763 | Trial comparisons |
| Spironolactone vs Standard of Care BP Treatment: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT01897727 | Trial comparisons |
Papers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0430034
GET https://conductscience.org/api/diseases/v1/HP_0430034/drugs